Biomedical Research and Therapy Logo

Biomedical Research and Therapy

Case report Open Access Logo

Extranodal primary CD20-negative diffuse large B-cell lymphoma with cytoplasmic p16 expression

Nguyen Van Hung 1, 2, *
Nguyen Thuy Huong 1, 2
Nguyen Tuan Thanh 3
Tran Ngoc Minh 1, 2
Dao Thi Luan 1, 2

  1. Department of Pathology, Hanoi Medical University, Vietnam. 1, Ton That Tung Street, Dong Da District, Ha Noi City, Viet Nam
  2. Department of Pathology, Hospital of Hanoi Medical University, Vietnam. 1, Ton That Tung Street, Dong Da District, Ha Noi City, Viet Nam
  3. Pathological and cytopathological Center, Bach Mai Hospital, 78, Giai Phong Street, Dong Da District, Ha Noi City, Viet Nam
Correspondence to: Nguyen Van Hung, Department of Pathology, Hanoi Medical University, Vietnam. 1, Ton That Tung Street, Dong Da District, Ha Noi City, Viet Nam; Department of Pathology, Hospital of Hanoi Medical University, Vietnam. 1, Ton That Tung Street, Dong Da District, Ha Noi City, Viet Nam. Email: [email protected].
Volume & Issue: Vol. 9 No. 6 (2022) | Page No.: 5089-5094 | DOI: 10.15419/bmrat.v9i6.743
Published: 2022-06-30

Online metrics

Statistics from the website

  • Abstract Views: 6685
  • Galley Views: 2209

Statistics from Dimensions

Statistics from PlumX
Copyright © 2022 by the author(s).

This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Extranodal primary CD20-negative diffuse large B-cell lymphoma (DLBCL) is a rare tumor. It often presents a diagnostic challenge for pathologists as the morphological features of neoplastic cells are similar to those of undifferentiated carcinoma or sarcoma cells. While several B-cell markers are commonly tested, expanding the panel of B-cell markers is necessary to ascertain definitive DLBCL diagnoses and would assist in decisions regarding treatment and prognoses. Several additional markers have been proposed, including several mutated genes commonly expressed in cancer cells, such as c-Myc, Bcl6/c-Myc, Bcl6, Bcl2 (double/triple expressors), as well as cytoplasmic p16.

Keywords: CD20-negative diffuse large B-cell lymphoma biomarkers p16 of cellular senescence double/triple expressors immunohistochemistry
Sorry, we can not display full-text of this article in HTML format for you right now. Please get the article in PDF format instead.

Comments